Longaeva
66 Hudson Blvd E, 21st Floor, New York City, NY, 10001, United States
Overview
Founded in 2024, Longaeva Partners LP (“Longaeva”) is a New York-based investment management firm dedicated to excellence in the global equity markets. Our mission is to create enduring value for our investors through thoughtful investment strategies while fostering meaningful partnerships. At Longaeva, we pride ourselves on being deeply fundamental domain experts and forward-thinking investors. By combining rigorous analysis with creativity, we identify what we believe are unique opportunities and adeptly navigate complex markets. Our team is passionate about building businesses that stand the test of time, underpinned by a strong commitment to continuous learning and development – we are always exploring, testing, and evolving. Longaeva is named after one of the oldest and most resilient living things, the longaeva pine, representing longevity, adaptability, and persistence.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 2
- Active investors
- 0
Investment portfolio
- Imperative Care
Participated · Convertible Note · Mar 2026
Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.
- Galvanize Therapeutics
Participated · Series C · Sep 2025
Galvanize Therapeutics develops and commercializes a pulsed electric field (PEF) platform that uses non-thermal, short-duration, highly focused electrical pulses to modulate biologic processes. Its lead programs include the Aliya® PEF system for solid tumors and RheOx® therapy for chronic bronchitis. The company is commercial-stage and intends to expand its commercial footprint in the United States. Galvanize plans to advance clinical and development activities across its oncology and chronic lung disease programs. Management says it will continue to innovate its novel, non-pharmacologic PEF platform to address unmet needs in patients underserved by pharmaceutical approaches. The company is based in Redwood City, California. Galvanize Therapeutics commercializes the Aliya Pulsed Electric Field (PEF) energy platform, a non-thermal high-voltage, high-frequency electrical system designed to alter cellular physiology for ablation and drug delivery. The company has multiple product lines: RheOx for chronic bronchitis (CE Mark, launched in select European hospitals), CENTAURI for cardiac arrhythmias (CE Mark, launching in Europe), and the Aliya system for soft tissue ablation (recent U.S. FDA 510(k) clearance, launching at select U.S. hospitals). Galvanize is also studying Aliya in immuno-oncology (preclinical and early clinical signals of immune activation) and developing a local drug-delivery system. The company was formed by ATP in 2022 through the merger of Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics and is headquartered in San Carlos, Calif. Management says it is investing to prove safety and demonstrate enhanced outcomes in initial clinical targets while exploring additional platform applications.
Team
No current team members are available.